

Intranasal Treatment of Central Nervous System Dysfu

Pharmaceutical Research

30, 2475-2484

DOI: [10.1007/s11095-012-0915-1](https://doi.org/10.1007/s11095-012-0915-1)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Intranasal Insulin as a Treatment for Alzheimer's Disease: A Review of Basic Research and Clinical Evidence. <i>CNS Drugs</i> , 2013, 27, 505-514.	2.7	402
2	Hippocampal calcium dysregulation at the nexus of diabetes and brain aging. <i>European Journal of Pharmacology</i> , 2013, 719, 34-43.	1.7	31
3	Accessing the Brain: The Nose may Know the Way. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013, 33, 793-794.	2.4	31
5	Intranasal insulin therapy for cognitive impairment and neurodegeneration: current state of the art. <i>Expert Opinion on Drug Delivery</i> , 2013, 10, 1699-1709.	2.4	68
6	Metabolic disturbances connecting obesity and depression. <i>Frontiers in Neuroscience</i> , 2013, 7, 177.	1.4	232
7	Helping oxytocin deliver: considerations in the development of oxytocin-based therapeutics for brain disorders. <i>Frontiers in Neuroscience</i> , 2013, 7, 35.	1.4	139
8	A New Brain Drug Delivery Strategy: Focused Ultrasound-Enhanced Intranasal Drug Delivery. <i>PLoS ONE</i> , 2014, 9, e108880.	1.1	40
9	The Oral and Intranasal Delivery of Propofol Using Chitosan Amphiphile Nanoparticles. <i>Pharmaceutical Nanotechnology</i> , 2014, 2, 65-74.	0.6	11
10	Intranasal Angiotensin II in Humans Reduces Blood Pressure When Angiotensin II Type 1 Receptors Are Blocked. <i>Hypertension</i> , 2014, 63, 762-767.	1.3	6
11	Intranasal Delivery of Bone Marrow-Derived Mesenchymal Stem Cells, Macrophages, and Microglia to the Brain in Mouse Models of Alzheimer's and Parkinson's Disease. <i>Cell Transplantation</i> , 2014, 23, 123-139.	1.2	114
12	Early Intervention With Intranasal NPY Prevents Single Prolonged Stress-Triggered Impairments in Hypothalamus and Ventral Hippocampus in Male Rats. <i>Endocrinology</i> , 2014, 155, 3920-3933.	1.4	63
13	Intranasal delivery of FSD-C10, a novel Rho kinase inhibitor, exhibits therapeutic potential in experimental autoimmune encephalomyelitis. <i>Immunology</i> , 2014, 143, 219-229.	2.0	24
14	Blockage of melanocortin4 receptors by intranasal HS014 attenuates single prolonged stress-triggered changes in several brain regions. <i>Journal of Neurochemistry</i> , 2014, 131, 825-835.	2.1	18
15	Emerging evidence of insulin-like growth factor 2 as a memory enhancer: a unique animal model of cognitive dysfunction with impaired adult neurogenesis. <i>Reviews in the Neurosciences</i> , 2014, 25, 559-74.	1.4	22
16	An intranasal herbal medicine improves executive functions and activates the underlying neural network in children with autism. <i>Research in Autism Spectrum Disorders</i> , 2014, 8, 681-691.	0.8	5
17	Targeting midkine and pleiotrophin signalling pathways in addiction and neurodegenerative disorders: recent progress and perspectives. <i>British Journal of Pharmacology</i> , 2014, 171, 837-848.	2.7	66
18	MALDI Mass Spectrometry Imaging of 1-Methyl-4-phenylpyridinium (MPP+) in Mouse Brain. <i>Neurotoxicity Research</i> , 2014, 25, 135-145.	1.3	27
19	Novel Central Nervous System Drug Delivery Systems. <i>Chemical Biology and Drug Design</i> , 2014, 83, 507-520.	1.5	90

#	ARTICLE	IF	CITATIONS
20	The nasal approach to delivering treatment for brain diseases: an anatomic, physiologic, and delivery technology overview. <i>Therapeutic Delivery</i> , 2014, 5, 709-733.	1.2	220
21	Precision Nanomedicine in Neurodegenerative Diseases. <i>ACS Nano</i> , 2014, 8, 1958-1965.	7.3	95
22	Insulin protects against A β ² -induced spatial memory impairment, hippocampal apoptosis and MAPKs signaling disruption. <i>Neuropharmacology</i> , 2014, 85, 113-120.	2.0	61
23	Mood, food, and obesity. <i>Frontiers in Psychology</i> , 2014, 5, 925.	1.1	262
24	Brain signaling systems in the Type 2 diabetes and metabolic syndrome: promising target to treat and prevent these diseases. <i>Future Science OA</i> , 2015, 1, FSO25.	0.9	54
25	The Effect of Long-Term Intranasal Serotonin Treatment on Metabolic Parameters and Hormonal Signaling in Rats with High-Fat Diet/Low-Dose Streptozotocin-Induced Type 2 Diabetes. <i>International Journal of Endocrinology</i> , 2015, 2015, 1-17.	0.6	54
26	Exogenous and evoked oxytocin restores social behavior in the <i>Cntnap2</i> mouse model of autism. <i>Science Translational Medicine</i> , 2015, 7, 271ra8.	5.8	308
27	Leptin Therapy as a Substitute for Insulin Replacement in Experimental Models of Diabetes: Clinical Implications in Humans. , 2015, , 255-265.		0
28	Methodology and effects of repeated intranasal delivery of DNSP-11 in a rat model of Parkinson's disease. <i>Journal of Neuroscience Methods</i> , 2015, 251, 120-129.	1.3	15
29	A Key Role of Insulin Receptors in Memory. <i>Diabetes</i> , 2015, 64, 3653-3655.	0.3	50
30	Prospects for polymer therapeutics in Parkinson's disease and other neurodegenerative disorders. <i>Progress in Polymer Science</i> , 2015, 44, 79-112.	11.8	24
31	Central Insulin Administration Improves Odor-Cued Reactivation of Spatial Memory in Young Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 212-219.	1.8	57
32	Emerging Insights for Translational Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Studies: Towards Prediction of Nose-to-Brain Transport in Humans. <i>AAPS Journal</i> , 2015, 17, 493-505.	2.2	79
33	Associations between insulin action and integrity of brain microstructure differ with familial longevity and with age. <i>Frontiers in Aging Neuroscience</i> , 2015, 7, 92.	1.7	3
34	Anatomy of the Trigeminal Nerve. , 2015, , 319-350.		6
35	Intranasal delivery of hypoxia-preconditioned bone marrow-derived mesenchymal stem cells enhanced regenerative effects after intracerebral hemorrhagic stroke in mice. <i>Experimental Neurology</i> , 2015, 272, 78-87.	2.0	107
36	Is Brain Insulin Action Relevant to the Control of Plasma Glucose in Humans?. <i>Diabetes</i> , 2015, 64, 696-699.	0.3	15
37	Brain delivery of small interfering ribonucleic acid and drugs through intranasal administration with nano-sized polymer micelles. <i>Medical Devices: Evidence and Research</i> , 2015, 8, 57.	0.4	29

#	ARTICLE	IF	CITATIONS
38	Intranasal delivery of bone marrow stromal cells to spinal cord lesions. <i>Journal of Neurosurgery: Spine</i> , 2015, 23, 111-119.	0.9	24
39	Neuroprotective Effect of VEGF-Mimetic Peptide QK in Experimental Brain Ischemia Induced in Rat by Middle Cerebral Artery Occlusion. <i>ACS Chemical Neuroscience</i> , 2015, 6, 1517-1525.	1.7	24
40	Position on zinc delivery to olfactory nerves in intranasal insulin phase III clinical trials. <i>Contemporary Clinical Trials</i> , 2015, 45, 277-280.	0.8	13
42	Leptin. , 2015, , .		4
43	Discovering and Developing Molecules with Optimal Drug-Like Properties. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2015, , .	0.2	8
44	Intranasal Insulin Enhanced Resting-State Functional Connectivity of Hippocampal Regions in Type 2 Diabetes. <i>Diabetes</i> , 2015, 64, 1025-1034.	0.3	132
45	In Vivo Administration of Cerebrospinal Fluid of Patients with Multiple Sclerosis; A New Model to Study Adult Neurogenesis in Different Stages of Disease. <i>Journal of Neurology and Neuroscience</i> , 2016, 7, .	0.4	0
46	Metabolic status and olfactory function. , 2016, , 315-335.		0
48	A review of intranasal formulations for the treatment of seizure emergencies. <i>Journal of Controlled Release</i> , 2016, 237, 147-159.	4.8	117
49	Insulin in the nervous system and the mind: Functions in metabolism, memory, and mood. <i>Molecular Metabolism</i> , 2016, 5, 589-601.	3.0	122
50	Intranasal insulin treatment improves memory and learning in a rat amyloid-beta model of Alzheimer's disease. <i>Physiology International</i> , 2016, 103, 344-353.	0.8	13
51	Preconditioning mesenchymal stem cells with the mood stabilizers lithium and valproic acid enhances therapeutic efficacy in a mouse model of Huntington's disease. <i>Experimental Neurology</i> , 2016, 281, 81-92.	2.0	57
52	Intranasal Oncolytic Virotherapy with CXCR4-Enhanced Stem Cells Extends Survival in Mouse Model of Glioma. <i>Stem Cell Reports</i> , 2016, 7, 471-482.	2.3	45
53	Nanomedicine as a non-invasive strategy for drug delivery across the blood brain barrier. <i>International Journal of Pharmaceutics</i> , 2016, 515, 331-342.	2.6	65
54	Treatment of cognitive dysfunction in adults with major depressive disorder. , 0, , 274-288.		1
55	Insulin potentiates the therapeutic effect of memantine against central STZ-induced spatial learning and memory deficit. <i>Behavioural Brain Research</i> , 2016, 311, 247-254.	1.2	10
56	Rapid intranasal delivery of chloramphenicol acetyltransferase in the active form to different brain regions as a model for enzyme therapy in the CNS. <i>Journal of Neuroscience Methods</i> , 2016, 259, 129-134.	1.3	12
57	Ionizing radiation-engineered nanogels as insulin nanocarriers for the development of a new strategy for the treatment of Alzheimer's disease. <i>Biomaterials</i> , 2016, 80, 179-194.	5.7	91

#	ARTICLE	IF	CITATIONS
58	Neuropeptide Y: A stressful review. <i>Neuropeptides</i> , 2016, 55, 99-109.	0.9	326
59	Efficacy and safety of oxytocin augmentation therapy for schizophrenia: an updated systematic review and meta-analysis of randomized, placebo-controlled trials. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2016, 266, 439-450.	1.8	39
60	Novel tactics for neuroprotection in Parkinson's disease: Role of antibiotics, polyphenols and neuropeptides. <i>Progress in Neurobiology</i> , 2017, 155, 120-148.	2.8	130
61	A strategy for bypassing the blood-brain barrier: Facial intradermal brain-targeted delivery via the trigeminal nerve. <i>Journal of Controlled Release</i> , 2017, 258, 22-33.	4.8	17
62	Limiting the level of tertiary amines on polyamines leads to biocompatible nucleic acid vectors. <i>International Journal of Pharmaceutics</i> , 2017, 526, 106-124.	2.6	15
63	Neuropeptide Y, resilience, and PTSD therapeutics. <i>Neuroscience Letters</i> , 2017, 649, 164-169.	1.0	62
64	Structure-specific effects of lipidated oxytocin analogs on intracellular calcium levels, parental behavior, and oxytocin concentrations in the plasma and cerebrospinal fluid in mice. <i>Pharmacology Research and Perspectives</i> , 2017, 5, e00290.	1.1	13
65	Nose to brain delivery in rats: Effect of surface charge of rhodamine B labeled nanocarriers on brain subregion localization. <i>Colloids and Surfaces B: Biointerfaces</i> , 2017, 154, 297-306.	2.5	64
66	Zinc gluconate toxicity in wild-type vs. MT1/2-deficient mice. <i>NeuroToxicology</i> , 2017, 58, 130-136.	1.4	5
67	Thermosensitive in situ nanocomposite of rivastigmine hydrogen tartrate as an intranasal delivery system: Development, characterization, ex vivo permeation and cellular studies. <i>Colloids and Surfaces B: Biointerfaces</i> , 2017, 159, 629-638.	2.5	45
68	Progress in brain targeting drug delivery system by nasal route. <i>Journal of Controlled Release</i> , 2017, 268, 364-389.	4.8	256
69	Intranasal delivery of dexamethasone efficiently controls LPS-induced murine neuroinflammation. <i>Clinical and Experimental Immunology</i> , 2017, 190, 304-314.	1.1	31
70	Enhancement of nose-to-brain delivery of hydrophilic macromolecules with stearate- or polyethylene glycol-modified arginine-rich peptide. <i>International Journal of Pharmaceutics</i> , 2017, 530, 195-200.	2.6	49
71	Repair of neonatal brain injury: bringing stem cell-based therapy into clinical practice. <i>Developmental Medicine and Child Neurology</i> , 2017, 59, 997-1003.	1.1	35
72	Effect of fasudil on cognitive function following status convulsion in rats. <i>Molecular Medicine Reports</i> , 2017, 16, 119-126.	1.1	8
73	The pertussis hypothesis: <i>Bordetella pertussis</i> colonization in the pathogenesis of Alzheimer's disease. <i>Immunobiology</i> , 2017, 222, 228-240.	0.8	18
74	Stem cell therapies in age-related neurodegenerative diseases and stroke. <i>Ageing Research Reviews</i> , 2017, 34, 39-50.	5.0	46
76	Olfactory Loss Management in View of Avicenna: Focus on Neuroprotective Plants. <i>Current Pharmaceutical Design</i> , 2017, 23, 3315-3321.	0.9	8

#	ARTICLE	IF	CITATIONS
77	Modulating Neurotrophin Receptor Signaling as a Therapeutic Strategy for Huntington's Disease. <i>Journal of Huntington's Disease</i> , 2017, 6, 303-325.	0.9	27
78	Intranasal BMP9 Ameliorates Alzheimer Disease-Like Pathology and Cognitive Deficits in APP/PS1 Transgenic Mice. <i>Frontiers in Molecular Neuroscience</i> , 2017, 10, 32.	1.4	19
79	Intranasal Cotinine Plus Krill Oil Facilitates Fear Extinction, Decreases Depressive-Like Behavior, and Increases Hippocampal Calcineurin A Levels in Mice. <i>Molecular Neurobiology</i> , 2018, 55, 7949-7960.	1.9	19
80	Increased acetylcholine and glutamate efflux in the prefrontal cortex following intranasal orexin (hypocretin). <i>Journal of Neurochemistry</i> , 2018, 145, 232-244.	2.1	22
81	Pharmacokinetics of Intranasal versus Subcutaneous Insulin in the Mouse. <i>ACS Chemical Neuroscience</i> , 2018, 9, 809-816.	1.7	28
82	Numerical Comparison of Nasal Aerosol Administration Systems for Efficient Nose-to-Brain Drug Delivery. <i>Pharmaceutical Research</i> , 2018, 35, 5.	1.7	30
83	Methodology and effects of repeated intranasal delivery of DNSP-11 in awake Rhesus macaques. <i>Journal of Neuroscience Methods</i> , 2018, 303, 30-40.	1.3	10
84	The Possible Effect of Oxytocin in Postpartum Recovery From a Stroke: A Case Report. <i>PM and R</i> , 2018, 10, 1422-1425.	0.9	5
85	Formulation Development and Evaluation of Diphenhydramine Nasal Nano-Emulgel. <i>AAPS PharmSciTech</i> , 2018, 19, 1730-1743.	1.5	16
86	Neuro-Nano Interfaces: Utilizing Nano-Coatings and Nanoparticles to Enable Next-Generation Electrophysiological Recording, Neural Stimulation, and Biochemical Modulation. <i>Advanced Functional Materials</i> , 2018, 28, 1700239.	7.8	38
87	Meta-analytic review of the effects of a single dose of intranasal oxytocin on threat processing in humans. <i>Journal of Affective Disorders</i> , 2018, 225, 167-179.	2.0	31
88	Intranasal insulin in Alzheimer's disease: Food for thought. <i>Neuropharmacology</i> , 2018, 136, 196-201.	2.0	77
89	Neuroprotective and Anti-inflammatory Effects of a Dodecamer Peptide Harboring Ninjurin 1 Cell Adhesion Motif in the Postischemic Brain. <i>Molecular Neurobiology</i> , 2018, 55, 6094-6111.	1.9	19
90	Nanoparticulate peptide delivery exclusively to the brain produces tolerance free analgesia. <i>Journal of Controlled Release</i> , 2018, 270, 135-144.	4.8	51
91	Systematic review and meta-analysis of reported adverse events of long-term intranasal oxytocin treatment for autism spectrum disorder. <i>Psychiatry and Clinical Neurosciences</i> , 2018, 72, 140-151.	1.0	49
92	Nose-to-brain peptide delivery – The potential of nanotechnology. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 2888-2905.	1.4	113
93	Comparison of the Structural Features of Micron and Submicron Vaterite Particles and Their Efficiency for Intranasal Delivery of Anesthetic to the Brain. <i>Crystallography Reports</i> , 2018, 63, 998-1004.	0.1	4
94	Evaluation of intranasal delivery route of drug administration for brain targeting. <i>Brain Research Bulletin</i> , 2018, 143, 155-170.	1.4	468

#	ARTICLE	IF	CITATIONS
95	Dual-use nano-neurotechnology. <i>Politics and the Life Sciences</i> , 2018, 37, 180-202.	0.5	12
96	Hyperforin improves post-stroke social isolation-induced exaggeration of PSD and PSA via TGF- β 2. <i>International Journal of Molecular Medicine</i> , 2019, 43, 413-425.	1.8	16
97	MRI and histological evaluation of pulsed focused ultrasound and microbubbles treatment effects in the brain. <i>Theranostics</i> , 2018, 8, 4837-4855.	4.6	53
98	Antidepressant-like effects of insulin and IGF-1 are mediated by IGF-1 receptors in the brain. <i>Brain Research Bulletin</i> , 2018, 143, 27-35.	1.4	21
99	Quantitative analysis of recombinant glucocerebrosidase brain delivery via lipid nanoparticles. <i>Nano Futures</i> , 2018, 2, 045003.	1.0	2
100	Autism is an Acquired Cellular Detoxification Deficiency Syndrome with Heterogeneous Genetic Predisposition. <i>Autism-open Access</i> , 2018, 08, .	0.2	1
101	Inhibitory Effects of Intranasal Administration of Insulin on Fat Oxidation during Exercise Are Diminished in Young Overweight Individuals. <i>Journal of Clinical Medicine</i> , 2018, 7, 308.	1.0	1
102	The Route by Which Intranasally Delivered Stem Cells Enter the Central Nervous System. <i>Cell Transplantation</i> , 2018, 27, 501-514.	1.2	65
103	Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs. <i>Journal of Controlled Release</i> , 2018, 281, 139-177.	4.8	377
104	Nervous System Injury in Response to Contact With Environmental, Engineered and Planetary Micro- and Nano-Sized Particles. <i>Frontiers in Physiology</i> , 2018, 9, 728.	1.3	47
105	Insulin Resistance as a Therapeutic Target in the Treatment of Alzheimer's Disease: A State-of-the-Art Review. <i>Frontiers in Neuroscience</i> , 2018, 12, 215.	1.4	67
106	Stem Cell Therapy: A Promising Therapeutic Method for Intracerebral Hemorrhage. <i>Cell Transplantation</i> , 2018, 27, 1809-1824.	1.2	55
107	Surface-Modified Nanocarriers for Nose-to-Brain Delivery: From Bioadhesion to Targeting. <i>Pharmaceutics</i> , 2018, 10, 34.	2.0	206
108	Hydrogels-Assisted Cell Engraftment for Repairing the Stroke-Damaged Brain: Chimera or Reality. <i>Polymers</i> , 2018, 10, 184.	2.0	28
109	Could the Olfactory System Be a Target for Homeopathic Remedies as Nanomedicines?. <i>Journal of Alternative and Complementary Medicine</i> , 2018, 24, 1032-1038.	2.1	5
110	Intranasal administration of progesterone: A potential efficient route of delivery for cerebroprotection after acute brain injuries. <i>Neuropharmacology</i> , 2019, 145, 283-291.	2.0	28
111	Envisioning the future of polymer therapeutics for brain disorders. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2019, 11, e1532.	3.3	17
112	Biliverdin Reductase-A Mediates the Beneficial Effects of Intranasal Insulin in Alzheimer Disease. <i>Molecular Neurobiology</i> , 2019, 56, 2922-2943.	1.9	70

#	ARTICLE	IF	CITATIONS
113	Modulation of Glucose Metabolism in Hippocampal Neurons by Adiponectin and Resistin. <i>Molecular Neurobiology</i> , 2019, 56, 3024-3037.	1.9	34
114	Stem Cells for Traumatic Brain Injury. , 2019, , 369-389.		2
115	Roles of Neuropeptide Y in Neurodegenerative and Neuroimmune Diseases. <i>Frontiers in Neuroscience</i> , 2019, 13, 869.	1.4	62
116	Intra-Nasally Administered Oligopeptide Lunasin Acts as a Possible Anti-Psychotic Agent in Mice Models. <i>Medicina (Lithuania)</i> , 2019, 55, 393.	0.8	1
117	Intranasal dopamine attenuates fear responses induced by electric shock to the foot and by electrical stimulation of the dorsal periaqueductal gray matter. <i>Journal of Psychopharmacology</i> , 2019, 33, 1524-1532.	2.0	7
118	Intranasal Treatment in Subarachnoid Hemorrhage. <i>Springer Series in Translational Stroke Research</i> , 2019, , 57-64.	0.1	0
119	Brain Targeting of Acyl-CoA:Cholesterol <i>Acyltransferase-1</i> Inhibitor K-604 via the Intranasal Route Using a Hydroxycarboxylic Acid Solution. <i>ACS Omega</i> , 2019, 4, 16943-16955.	1.6	12
120	Toxic exposures and the senses of taste and smell. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2019, 164, 389-408.	1.0	26
121	Presymptomatic Treatment With Andrographolide Improves Brain Metabolic Markers and Cognitive Behavior in a Model of Early-Onset Alzheimer's Disease. <i>Frontiers in Cellular Neuroscience</i> , 2019, 13, 295.	1.8	34
122	Brain insulin resistance: A treatment target for cognitive impairment and anhedonia in depression. <i>Experimental Neurology</i> , 2019, 315, 1-8.	2.0	82
123	Nose-to-Brain Delivery. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 370, 593-601.	1.3	141
124	Therapeutic Potential of Oxytocin in Atherosclerotic Cardiovascular Disease: Mechanisms and Signaling Pathways. <i>Frontiers in Neuroscience</i> , 2019, 13, 454.	1.4	58
125	Therapeutic Intranasal Delivery for Stroke and Neurological Disorders. <i>Springer Series in Translational Stroke Research</i> , 2019, , .	0.1	3
126	Intranasal dolutegravir sodium loaded nanoparticles of hydroxypropyl-beta-cyclodextrin for brain delivery in Neuro-AIDS. <i>Journal of Drug Delivery Science and Technology</i> , 2019, 52, 1008-1020.	1.4	30
127	Considerations for the Use of Polyphenols as Therapies in Neurodegenerative Diseases. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1883.	1.8	87
128	Drug delivery to the brain. , 2019, , 461-514.		9
129	Surface-Modified PLGA Nanoparticles for Targeted Drug Delivery to Neurons. , 2019, , 33-71.		8
130	In Vitro Enzymatic Digestibility of Glutaraldehyde-Crosslinked Chitosan Nanoparticles in Lysozyme Solution and Their Applicability in Pulmonary Drug Delivery. <i>Molecules</i> , 2019, 24, 1271.	1.7	57

#	ARTICLE	IF	CITATIONS
131	Nasal delivery of Fasudilâ€modified immune cells exhibits therapeutic potential in experimental autoimmune encephalomyelitis. <i>CNS Neuroscience and Therapeutics</i> , 2019, 25, 783-795.	1.9	11
132	Nasal Drug Delivery of Anticancer Drugs for the Treatment of Glioblastoma: Preclinical and Clinical Trials. <i>Molecules</i> , 2019, 24, 4312.	1.7	77
133	Blood-Brain Barrier: From Physiology to Disease and Back. <i>Physiological Reviews</i> , 2019, 99, 21-78.	13.1	1,232
134	Intranasal breast milk for premature infants with severe intraventricular hemorrhageâ€an observation. <i>European Journal of Pediatrics</i> , 2019, 178, 199-206.	1.3	26
135	Sepsis: developing new alternatives to reduce neuroinflammation and attenuate brain injury. <i>Annals of the New York Academy of Sciences</i> , 2019, 1437, 43-56.	1.8	59
136	Clinical Evidence of Antidepressant Effects of Insulin and Anti-Hyperglycemic Agents and Implications for the Pathophysiology of Depressionâ€A Literature Review. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6969.	1.8	18
137	The role of exercise-induced peripheral factors in sleep regulation. <i>Molecular Metabolism</i> , 2020, 42, 101096.	3.0	21
138	A Randomized Controlled Trial of Intranasal Neuropeptide Y in Patients With Major Depressive Disorder. <i>International Journal of Neuropsychopharmacology</i> , 2020, 23, 783-790.	1.0	23
139	Intranasal delivery of Thyroid hormones in MCT8 deficiency. <i>PLoS ONE</i> , 2020, 15, e0236113.	1.1	9
140	Age-Related Olfactory Dysfunction: Epidemiology, Pathophysiology, and Clinical Management. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 208.	1.7	62
141	Stability of extemporaneously compounded amiloride nasal spray. <i>PLoS ONE</i> , 2020, 15, e0232435.	1.1	10
142	Probing the drug delivery strategies in ischemic stroke therapy. <i>Drug Delivery</i> , 2020, 27, 1644-1655.	2.5	18
143	Loss of Olfactory Functionâ€Early Indicator for Covid-19, Other Viral Infections and Neurodegenerative Disorders. <i>Frontiers in Neurology</i> , 2020, 11, 569333.	1.1	42
144	Role of Insulin in Neurotrauma and Neurodegeneration: A Review. <i>Frontiers in Neuroscience</i> , 2020, 14, 547175.	1.4	34
145	Effects of haloperidol inhalation on MK-801- and memantine-induced locomotion in mice. <i>Libyan Journal of Medicine</i> , 2020, 15, 1808361.	0.8	3
146	In vivo assessment of cerebrospinal fluid efflux to nasal mucosa in humans. <i>Scientific Reports</i> , 2020, 10, 14974.	1.6	35
147	Neurotherapeutic applications of nanomedicine for treating Alzheimer's disease. <i>Journal of Controlled Release</i> , 2020, 325, 25-37.	4.8	38
148	Intranasal delivery of berberine <i>via in situ</i> thermoresponsive hydrogels with non-invasive therapy exhibits better antidepressant-like effects. <i>Biomaterials Science</i> , 2020, 8, 2853-2865.	2.6	28

#	ARTICLE	IF	CITATIONS
149	An Overview of Crucial Dietary Substances and Their Modes of Action for Prevention of Neurodegenerative Diseases. <i>Cells</i> , 2020, 9, 576.	1.8	20
150	Nasal delivery nanoparticles. , 2020, , 89-101.		0
151	Increase in diastolic blood pressure induced by fragrance inhalation of grapefruit essential oil is positively correlated with muscle sympathetic nerve activity. <i>Journal of Physiological Sciences</i> , 2020, 70, 2.	0.9	22
152	Polymeric Nanoparticles for the Treatment of Malignant Gliomas. <i>Cancers</i> , 2020, 12, 175.	1.7	63
153	Novel approaches for the delivery of therapeutics in ischemic stroke. <i>Drug Discovery Today</i> , 2020, 25, 535-551.	3.2	32
154	Effects of Intranasal Orexin-A (Hypocretin-1) Administration on Neuronal Activation, Neurochemistry, and Attention in Aged Rats. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 362.	1.7	14
155	Modulation of nose-to-brain delivery of a P-glycoprotein (MDR1) substrate model drug (quinidine) in rats. <i>Brain Research Bulletin</i> , 2020, 160, 65-73.	1.4	27
156	An in vitro and in vivo study of the brain-targeting effects of an epidermal growth factor-functionalized cholera toxin-like chimeric protein. <i>Journal of Controlled Release</i> , 2020, 322, 509-518.	4.8	11
157	Insulin and leptin as potential cognitive enhancers in metabolic disorders and Alzheimer's disease. <i>Neuropharmacology</i> , 2020, 171, 108115.	2.0	27
158	Applications of direct nose-to-brain drug delivery in biomedicine, biotechnology, tissue engineering, and immunology. , 2021, , 267-285.		0
160	Olfactory mucosa stem cells delivery via nasal route: a simple way for the treatment of Parkinson disease. <i>Neurotoxicity Research</i> , 2021, 39, 598-608.	1.3	15
161	Intranasal drug delivery for treatment of Alzheimer's disease. <i>Drug Delivery and Translational Research</i> , 2021, 11, 411-425.	3.0	34
162	Nose-to-brain delivery of disulfiram nanoemulsion in situ gel formulation for glioblastoma targeting therapy. <i>International Journal of Pharmaceutics</i> , 2021, 597, 120250.	2.6	27
163	First-line management of canine status epilepticus at home and in hospital-opportunities and limitations of the various administration routes of benzodiazepines. <i>BMC Veterinary Research</i> , 2021, 17, 103.	0.7	16
164	Evolving new-age strategies to transport therapeutics across the blood-brain-barrier. <i>International Journal of Pharmaceutics</i> , 2021, 599, 120351.	2.6	29
165	Magnetic Targeting of Human Olfactory Mucosa Stem Cells Following Intranasal Administration: a Novel Approach to Parkinson's Disease Treatment. <i>Molecular Neurobiology</i> , 2021, 58, 3835-3847.	1.9	17
166	Intranasal insulin and orexins to treat age-related cognitive decline. <i>Physiology and Behavior</i> , 2021, 234, 113370.	1.0	15
167	Computational analysis of a 3D mucociliary clearance model predicting nasal drug uptake. <i>Journal of Aerosol Science</i> , 2021, 155, 105757.	1.8	17

#	ARTICLE	IF	CITATIONS
168	Brain insulin signalling in metabolic homeostasis and disease. <i>Nature Reviews Endocrinology</i> , 2021, 17, 468-483.	4.3	70
169	Cerebral ischemic stroke and different approaches for treatment of stroke. <i>Future Journal of Pharmaceutical Sciences</i> , 2021, 7, .	1.1	4
170	Structure and Fate of Nanoparticles Designed for the Nasal Delivery of Poorly Soluble Drugs. <i>Molecular Pharmaceutics</i> , 2021, 18, 3132-3146.	2.3	37
171	The Potential Benefits of Nanotechnology in Treating Alzheimer's Disease. <i>BioMed Research International</i> , 2021, 2021, 1-9.	0.9	24
172	Sex differences in the cerebroprotection by Nestorone intranasal delivery following stroke in mice. <i>Neuropharmacology</i> , 2021, 198, 108760.	2.0	5
173	Neuropeptide Y Y2 and Y5 receptors as potential targets for neuroprotective and antidepressant therapies: Evidence from preclinical studies. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 111, 110349.	2.5	11
174	Potential applications of nanomedicine for treating Parkinson's disease. <i>Journal of Drug Delivery Science and Technology</i> , 2021, 66, 102793.	1.4	7
175	Discovery Formulations: Approaches and Practices in Early Preclinical Development. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2015, , 49-94.	0.2	8
176	Intranasal Drug Delivery After Intracerebral Hemorrhage. <i>Springer Series in Translational Stroke Research</i> , 2019, , 43-55.	0.1	1
177	Role of Feed-Forward Inhibition in Neocortical Information Processing: Implications for Neurological Disorders. <i>Springer Series in Cognitive and Neural Systems</i> , 2017, , 383-397.	0.1	4
178	Effects of ghrelin agonist and antagonist on endogenous desacyl-ghrelin content in the brain limbic structures under psychoemotional stress in rats. <i>Reviews on Clinical Pharmacology and Drug Therapy</i> , 2017, 15, 22-27.	0.2	1
179	Intranasal Nanoparticulate Systems as Alternative Route of Drug Delivery. <i>Current Medicinal Chemistry</i> , 2019, 26, 6459-6492.	1.2	59
180	Oxytocin - A Multifunctional Analgesic for Chronic Deep Tissue Pain. <i>Current Pharmaceutical Design</i> , 2014, 21, 906-913.	0.9	50
181	The Role of Intranasal Oxytocin in the Treatment of Patients with Schizophrenia: A Systematic Review. <i>CNS and Neurological Disorders - Drug Targets</i> , 2013, 12, 252-264.	0.8	32
182	Road From Nose to Brain for Treatment of Alzheimer: The Bumps and Humps. <i>CNS and Neurological Disorders - Drug Targets</i> , 2020, 19, 663-675.	0.8	5
183	Neurologic Stem Cell Treatment Study (NEST) using bone marrow derived stem cells for the treatment of neurological disorders and injuries: study protocol for a nonrandomized efficacy trial. <i>Clinical Trials in Degenerative Diseases</i> , 2016, 1, 176.	0.1	7
184	The Search for Incapacitants. , 2015, , 110-122.		0
185	Intranasal Delivery of Drugs for Ischemic Stroke Treatment: Targeting IL-17A. <i>Springer Series in Translational Stroke Research</i> , 2019, , 91-99.	0.1	0

#	ARTICLE	IF	CITATIONS
187	Oxytocin Blocks Opioid Withdrawal Symptoms Only When Combined with Group Therapy: A Double-Blind, Randomized Controlled Clinical Trial. Iranian Journal of Psychiatry and Behavioral Sciences, 2020, 14, .	0.1	2
188	Interlink Between Insulin Resistance and Neurodegeneration with an Update on Current Therapeutic Approaches. CNS and Neurological Disorders - Drug Targets, 2020, 19, 174-183.	0.8	6
189	Nanoengineering of stem cells for neural regenerative medicine. , 2020, , 159-211.		0
190	Role of Olfaction for Eating Behavior. , 2020, , 675-716.		5
191	Polyphenols as Potential Therapeutic Drugs in Neurodegeneration. , 0, , .		1
193	Imaging of intranasal drug delivery to the brain. American Journal of Nuclear Medicine and Molecular Imaging, 2020, 10, 1-31.	1.0	20
194	Intranasal orexin A modulates sympathetic vascular tone: a pilot study in healthy male humans. Journal of Neurophysiology, 2022, 127, 548-558.	0.9	5
195	Brain-derived neurotrophic factor in Alzheimer's disease and its pharmaceutical potential. Translational Neurodegeneration, 2022, 11, 4.	3.6	117
196	Convolutions in the rendition of nose to brain therapeutics from bench to bedside: Feats & fallacies. Journal of Controlled Release, 2022, 341, 782-811.	4.8	18
197	Intranasal application of stem cells and their derivatives as a new hope in the treatment of cerebral hypoxia/ischemia: a review. Reviews in the Neurosciences, 2022, 33, 583-606.	1.4	9
198	Olfactory dysfunction as a post-infectious symptom of SARS-CoV-2 infection. Annals of Medicine and Surgery, 2022, 75, 103352.	0.5	14
199	Intranasal Delivery of Galanin 2 and Neuropeptide Y1 Agonists Enhanced Spatial Memory Performance and Neuronal Precursor Cells Proliferation in the Dorsal Hippocampus in Rats. Frontiers in Pharmacology, 2022, 13, 820210.	1.6	7
200	Emerging therapies for brain recovery after IVH in neonates: Cord blood derived Mesenchymal Stem Cells (MSC) and Unrestricted Somatic Stem Cells (USSC). Seminars in Perinatology, 2022, 46, 151598.	1.1	2
201	Nose to Brain Drug Delivery System. Research Journal of Pharmaceutical Dosage Forms and Technology, 2021, , 335-340.	0.1	1
205	Brain Gene Silencing with Cationic Amino-Capped Poly(Ethylene Glycol) Polyplexes. SSRN Electronic Journal, 0, , .	0.4	0
206	A non-invasive direct nose to brain drug delivery platform vs. invasive brain delivery approach: patient-centered care impact analysis. Drug Delivery, 2022, 29, 1754-1763.	2.5	4
207	Gene Targeting to the Cerebral Cortex Following Intranasal Administration of Polyplexes. Pharmaceutics, 2022, 14, 1136.	2.0	4
208	Intranasal Methylprednisolone Ameliorates Neuroinflammation Induced by Chronic Toluene Exposure. Pharmaceutics, 2022, 14, 1195.	2.0	3

#	ARTICLE	IF	CITATIONS
209	Oxytocin-cholinergic central interaction: implications for non-social memory formation. <i>Neuroscience</i> , 2022, , .	1.1	1
210	Formulation and Characterization of Nanostructured Lipid Carriers of Rizatriptan Benzoate-Loaded <i>In Situ</i> Nasal Gel for Brain Targeting. <i>Assay and Drug Development Technologies</i> , 2022, 20, 211-224.	0.6	6
211	Polymeric nanocarriers for nose-to-brain drug delivery in neurodegenerative diseases and neurodevelopmental disorders. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 1866-1886.	5.7	23
212	Investigation of the "Nose-to-Brain" Pathways in Intranasal HupA Nanoemulsions and Evaluation of Their in vivo Pharmacokinetics and Brain-Targeting Ability. <i>International Journal of Nanomedicine</i> , 0, Volume 17, 3443-3456.	3.3	7
213	Active Pharmaceutical Ingredients Transportation and Release from Aerogel Particles Processes Modeling. <i>Computation</i> , 2022, 10, 139.	1.0	5
214	Biopolymer Nanoparticles for Nose-to-Brain Drug Delivery: A New Promising Approach for the Treatment of Neurological Diseases. <i>Journal of Functional Biomaterials</i> , 2022, 13, 125.	1.8	17
215	Nanocarrier facilitated drug delivery to the brain through intranasal route: A promising approach to transcend bio-obstacles and alleviate neurodegenerative conditions. <i>Journal of Drug Delivery Science and Technology</i> , 2022, 75, 103656.	1.4	5
216	Diabetes and associated cognitive disorders: Role of the Hypothalamic-Pituitary Adrenal axis. <i>Metabolism Open</i> , 2022, 15, 100202.	1.4	3
217	The metabolic status and olfactory function. , 2023, , 381-406.		0
218	Brain Gene Silencing with Cationic Amino-Capped Poly(ethylene glycol) Polyplexes. <i>Biomedicines</i> , 2022, 10, 2182.	1.4	3
219	Oxidative Stress and Mitochondrial Complex I Dysfunction Correlate with Neurodegeneration in an Î±-Synucleinopathy Animal Model. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11394.	1.8	12
220	A comprehensive review on carrier mediated nose to brain targeting: emphasis on molecular targets, current trends, future prospects, and challenges. <i>International Journal of Polymeric Materials and Polymeric Biomaterials</i> , 2024, 73, 91-103.	1.8	2
221	L-Cysteine Modified Chitosan Nanoparticles and Carbon-Based Nanostructures for the Intranasal Delivery of Galantamine. <i>Polymers</i> , 2022, 14, 4004.	2.0	4
222	Application of the intranasal road of administration for delivery of drugs to the central nervous system. <i>Reviews on Clinical Pharmacology and Drug Therapy</i> , 2022, 20, 281-288.	0.2	2
223	Alzheimer's Disease: Treatment Strategies and Their Limitations. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13954.	1.8	66
224	Intranasal Peptide Therapeutics: A Promising Avenue for Overcoming the Challenges of Traditional CNS Drug Development. <i>Cells</i> , 2022, 11, 3629.	1.8	8
225	Cannabidiol for the Treatment of Brain Disorders: Therapeutic Potential and Routes of Administration. <i>Pharmaceutical Research</i> , 2023, 40, 1087-1114.	1.7	8
226	GALR2 and Y1R agonists intranasal infusion enhanced adult ventral hippocampal neurogenesis and antidepressant-like effects involving BDNF actions. <i>Journal of Cellular Physiology</i> , 2023, 238, 459-474.	2.0	4

#	ARTICLE	IF	CITATIONS
227	Emerging Selenium Nanoparticles for CNS Intervention. , 0, , .		0
228	Role of Nanomedicine-Based Therapeutics in the Treatment of CNS Disorders. <i>Molecules</i> , 2023, 28, 1283.	1.7	5
229	Decreased medial prefrontal cortex activity related to impaired novel object preference task performance following GALR2 and Y1R agonists intranasal infusion. <i>Biomedicine and Pharmacotherapy</i> , 2023, 161, 114433.	2.5	1
230	Nasal Oxytocinâ€™s Anticonvulsant Effects on Pentylentetrazol- induced Convulsions in Rats. <i>International Journal of Pharmacology</i> , 2023, 19, 178-184.	0.1	0
231	Transcranial application of magnetic pulses for improving brain drug delivery efficiency via intranasal injection of magnetic nanoparticles. <i>Biomedical Engineering Letters</i> , 0, , .	2.1	0
232	Clinical correlates and metabolic indicators of elevated fasting glucose in overweight/obese Chinese Han patients with first-episode and drug-naive major depressive disorder. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	1
233	Pharmacokinetics of intranasal amiloride in healthy volunteers. <i>Clinical and Translational Science</i> , 2023, 16, 1075-1084.	1.5	3
234	An overview of current drug delivery strategies for glioblastoma treatment and barriers to progress. , 2023, , 405-434.		0
236	Nose-to-brain drug delivery for the treatment of CNS disease: New development and strategies. <i>International Review of Neurobiology</i> , 2023, , 255-297.	0.9	2